It can be hypothesized that breast cancer resistant to CDK4/6 inhibitors acquires cross-resistance to chemotherapeutic agents and reduces post-progression survival after CDK4/6 inhibitor therapies. This evidence concerns the gene CDK4 and breast carcinoma.